Database
2,324 programs· non-cancer programs, FDA-approved drugs, drugs still in development hidden
| Molecule | ||||||
|---|---|---|---|---|---|---|
veliparib Ovarian Cancer Business / strategicNCT02470585 | Phase 3 | AbbVie | — | 89 | ||
PI-88 Cancer Business / strategicNCT01402908 | Phase 3 | Cellxpert Biotechnology Corp. | — | 85 | ||
melflufen Relapsed Multiple Myeloma Business / strategicNCT04649060 | Phase 3 | Oncopeptides AB | — | 83 | ||
sitravatinib Urothelial Carcinoma Business / strategicNCT03606174 | Phase 2 | Mirati Therapeutics Inc. | — | 83 | ||
alvocidib Acute Myeloid Leukemia Accrual failureNCT02520011 | Phase 2 | Sumitomo Pharma America, Inc. | — | 83 | ||
Cilengitide Adult Giant Cell Glioblastoma Accrual failureNCT00112866 | Phase 2 | National Cancer Institute (NCI) | — | 82 | ||
formerly as RP5307 Chronic Lymphocytic Leukemia Business / strategicNCT02742090 | Phase 2 | TG Therapeutics, Inc. | — | 81 | ||
TAK-981 Neoplasms Accrual failureNCT03648372 | Phase 1/2 | Takeda | — | 80 | ||
ulixertinib Advanced Solid Tumor Accrual failureNCT04488003 | Phase 2 | BioMed Valley Discoveries, Inc | — | 80 | ||
NKTR-214 Renal Cell Carcinoma Business / strategicNCT03729245 | Phase 3 | Nektar Therapeutics | — | 80 | ||
TAK-981 Relapsed and/or Refractory Multiple Myeloma (RRMM) Business / strategicNCT04776018 | Phase 1/2 | Takeda | — | 79 | ||
Cebranopadol Pain Accrual failureNCT01964378 | Phase 3 | Tris Pharma, Inc. | — | 79 | ||
NKTR-214 Melanoma Business / strategicNCT04410445 | Phase 3 | Nektar Therapeutics | — | 79 | ||
apaziquone Bladder Cancer Business / strategicNCT01469221 | Phase 3 | Spectrum Pharmaceuticals, Inc | — | 78 | ||
131I-omburtamab Neuroblastoma Business / strategicNCT03275402 | Phase 2/3 | Y-mAbs Therapeutics | — | 78 | ||
robatumumab Osteosarcoma Business / strategicNCT00617890 | Phase 2 | Merck Sharp & Dohme LLC | — | 78 | ||
rovalpituzumab tesirine Malignant Melanoma Business / strategicNCT02709889 | Phase 1/2 | AbbVie | — | 78 | ||
formerly as RP5307 Chronic Lymphocytic Leukemia Accrual failureNCT04149821 | Phase 2 | Weill Medical College of Cornell University | — | 77 | ||
plitidepsin Multiple Myeloma Accrual failureNCT03117361 | Phase 2 | PharmaMar | — | 77 | ||
alvocidib Myelodysplastic Syndromes (MDS) Business / strategicNCT03593915 | Phase 1/2 | Sumitomo Pharma America, Inc. | — | 77 | ||
TAK-981 Lymphoma, Non-Hodgkin Accrual failureNCT04074330 | Phase 1/2 | Takeda | — | 77 | ||
7-hydroxystaurosporine Lymphoma, Large-Cell, Ki-1 Accrual failureNCT00082017 | Phase 2 | National Cancer Institute (NCI) | — | 77 | ||
melflufen Renal Impairment Business / strategicNCT03639610 | Phase 2 | Oncopeptides AB | — | 77 | ||
Investigational Agent Solid Tumor OperationalNCT04111107 | Phase 2 | Wake Forest University Health Sciences | — | 77 | ||
Lucitanib Breast Cancer Business / strategicNCT02202746 | Phase 2 | Clovis Oncology, Inc. | — | 77 | ||
Entospletinib MM Chronic Lymphocytic Leukemia Business / strategicNCT01799889 | Phase 2 | Gilead Sciences | — | 77 | ||
alvocidib Acute Myeloid Leukemia (AML) Business / strategicNCT03969420 | Phase 2 | Sumitomo Pharma America, Inc. | — | 76 | ||
Photodynamic therapy-Photofrin Hilar Cholangiocarcinoma Accrual failureNCT02082522 | Phase 3 | Concordia Laboratories Inc. | — | 76 | ||
Deupirfenidone Breast Cancer Related Lymphoedema Business / strategicNCT04243837 | Phase 2 | PureTech | — | 76 | ||
melflufen Multiple Myeloma Business / strategicNCT03481556 | Phase 1/2 | Oncopeptides AB | — | 76 | ||
Calmangafodipir (5 µmol/kg) Colorectal Cancer Business / strategicNCT04034355 | Phase 3 | Egetis Therapeutics | — | 76 | ||
RG1507 Sarcoma Business / strategicNCT00642941 | Phase 2 | Hoffmann-La Roche | — | 76 | ||
formerly as RP5307 Follicular Lymphoma OperationalNCT03178201 | Phase 2 | Columbia University | — | 75 | ||
ganetespib Melanoma Accrual failureNCT01551693 | Phase 2 | Dana-Farber Cancer Institute | — | 75 | ||
birinapant Epithelial Ovarian Cancer Accrual failureNCT01681368 | Phase 2 | National Cancer Institute (NCI) | — | 75 | ||
Mithramycin Lung Cancer Accrual failureNCT01624090 | Phase 2 | National Cancer Institute (NCI) | — | 75 | ||
motexafin gadolinium Non-Hodgkin's Lymphoma (NHL) Funding lostNCT00089284 | Phase 1/2 | Northwestern University | — | 75 | ||
olaratumab Gastrointestinal Stromal Tumor (GIST) Accrual failureNCT01316263 | Phase 2 | Eli Lilly and Company | — | 75 | ||
Xevinapant Head and Neck Cancer Business / strategicNCT05386550 | Phase 3 | EMD Serono Research & Development Institute, Inc. | — | 75 | ||
Dose Escalation Phase Advanced or Metastatic Solid Tumors OperationalNCT03316638 | Phase 1/2 | Pierre Fabre Medicament | — | 75 | ||
chimeric antigen receptor T cell Acute Lymphoblastic Leukemia Business / strategicNCT04340154 | Phase 2 | Beijing Boren Hospital | — | 75 | ||
brivanib Advanced Hepatocellular Carcinoma (HCC) Business / strategicNCT04212221 | Phase 1/2 | Zai Lab (Shanghai) Co., Ltd. | — | 75 | ||
CNF1010 (17-AAG) Recurrent Breast Cancer Accrual failureNCT00096109 | Phase 2 | National Cancer Institute (NCI) | — | 74 | ||
Ganglioside-Monosialic Acid Chemotherapy-Related Cognitive Impairment Accrual failureNCT05239663 | Phase 3 | Sun Yat-sen University | — | 74 | ||
pevonedistat Acute Myeloid Leukemia (AML) Funding lostNCT03709576 | Phase 2 | Milton S. Hershey Medical Center | — | 74 | ||
plitidepsin Prostate Cancer Accrual failureNCT00780975 | Phase 2 | PharmaMar | — | 74 | ||
plitidepsin Lymphoma Accrual failureNCT03070964 | Phase 2 | PharmaMar | — | 74 | ||
enzastaurin Breast Cancer Accrual failureNCT00536939 | Phase 2 | Eli Lilly and Company | — | 74 | ||
IPI-504 Lung Cancer Accrual failureNCT01228435 | Phase 2 | Massachusetts General Hospital | — | 74 | ||
LY2584702 Advanced Cancer Technical / PK / formulationNCT01394003 | Phase 1 | Eli Lilly and Company | — | 74 | ||
HSV-Tk Acute Leukemia (Category) Business / strategicNCT00914628 | Phase 3 | AGC Biologics S.p.A. | — | 74 | ||
apaziquone Bladder Cancer Business / strategicNCT01410565 | Phase 3 | Spectrum Pharmaceuticals, Inc | — | 74 | ||
Qapzola Bladder Cancer Business / strategicNCT03224182 | Phase 3 | Spectrum Pharmaceuticals, Inc | — | 74 | ||
formerly as RP5307 Non Hodgkin Lymphoma Business / strategicNCT03671590 | Phase 1 | TG Therapeutics, Inc. | — | 74 | ||
OPL-002 Colitis, Ulcerative Business / strategicNCT05156125 | Phase 2 | Oppilan Pharma Ltd | — | 74 | ||
amatuximab Mesothelioma, Malignant Business / strategicNCT02357147 | Phase 2 | Morphotek | — | 74 | ||
melflufen Multiple Myeloma UndisclosedNCT03151811 | Phase 3 | Oncopeptides AB | — | 74 | ||
BR55 Ovarian Cancer Business / strategicNCT04248153 | Phase 2 | Bracco Diagnostics, Inc | — | 73 | ||
BR55 Ovarian Cancer Business / strategicNCT03493464 | Phase 2 | Bracco Diagnostics, Inc | — | 73 | ||
sitravatinib Breast Cancer Stage IV Business / strategicNCT04123704 | Phase 2 | Xiang Zhang | — | 73 |
